ALNY
Price:
$246.78
Market Cap:
$31.68B
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1)...[Read more]
Industry
Biotechnology
IPO Date
2004-06-01
Stock Exchange
NASDAQ
Ticker
ALNY
According to Alnylam Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is 47.92%. This represents a change of -65.41% compared to the average of 138.54% of the last 4 quarters.
The mean historical ROE of Alnylam Pharmaceuticals, Inc. over the last ten years is 43.11%. The current 47.92% ROE has changed 11.15% with respect to the historical average. Over the past ten years (40 quarters), ALNY's ROE was at its highest in in the September 2022 quarter at 600.14%. The ROE was at its lowest in in the June 2022 quarter at -157.58%.
Average
43.11%
Median
-41.53%
Minimum
-144.99%
Maximum
714.91%
Discovering the peaks and valleys of Alnylam Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 110.47%
Maximum Annual ROE = 714.91%
Minimum Annual Increase = -593.08%
Minimum Annual ROE = -144.99%
Year | ROE | Change |
---|---|---|
2023 | 199.53% | -72.09% |
2022 | 714.91% | -593.08% |
2021 | -144.99% | 71.67% |
2020 | -84.46% | 37.12% |
2019 | -61.59% | 5.31% |
2018 | -58.49% | 110.47% |
2017 | -27.79% | -37.65% |
2016 | -44.57% | 94.31% |
2015 | -22.94% | -40.42% |
2014 | -38.49% | 16.63% |
The current ROE of Alnylam Pharmaceuticals, Inc. (ALNY) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
256.48%
5-year avg
124.68%
10-year avg
43.11%
Alnylam Pharmaceuticals, Inc.’s ROE is greater than ProQR Therapeutics N.V. (-55.21%), greater than Wave Life Sciences Ltd. (-657.91%), greater than Blueprint Medicines Corporation (-85.25%), greater than Apellis Pharmaceuticals, Inc. (-139.02%), less than Incyte Corporation (2.10%), less than United Therapeutics Corporation (18.82%), greater than Ultragenyx Pharmaceutical Inc. (-266.02%), less than BioMarin Pharmaceutical Inc. (5.08%), greater than Seagen Inc. (-28.06%), less than Exelixis, Inc. (15.80%), less than Halozyme Therapeutics, Inc. (168.60%), less than Krystal Biotech, Inc. (13.36%), greater than Madrigal Pharmaceuticals, Inc. (-95.61%), less than Reata Pharmaceuticals, Inc. (19.32%), greater than IVERIC bio, Inc. (-38.66%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%), greater than Karuna Therapeutics, Inc. (-30.79%), greater than Day One Biopharmaceuticals, Inc. (-122.70%),
Company | ROE | Market cap |
---|---|---|
-55.21% | $151.52M | |
-657.91% | $639.91M | |
-85.25% | $5.47B | |
-139.02% | $5.00B | |
2.10% | $11.80B | |
18.82% | $15.38B | |
-266.02% | $5.09B | |
5.08% | $16.01B | |
-28.06% | $43.15B | |
15.80% | $7.17B | |
168.60% | $7.50B | |
13.36% | $5.29B | |
-95.61% | $5.30B | |
19.32% | $6.57B | |
-38.66% | $5.51B | |
-46.15% | $161.36M | |
-30.79% | $12.60B | |
-122.70% | $1.25B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Alnylam Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Alnylam Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Alnylam Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Alnylam Pharmaceuticals, Inc. (ALNY)?
What is the highest ROE for Alnylam Pharmaceuticals, Inc. (ALNY)?
What is the 3-year average ROE for Alnylam Pharmaceuticals, Inc. (ALNY)?
What is the 5-year average ROE for Alnylam Pharmaceuticals, Inc. (ALNY)?
How does the current ROE for Alnylam Pharmaceuticals, Inc. (ALNY) compare to its historical average?